Dutasteride and Nandrolone Interaction: Avoid | Peptide Database

Nandrolone (Deca-Durabolin and NPP) elevates prolactin through progestogenic activity. Pramipexole can be used as an alternative to cabergoline for managing prolactin-related side effects including sexual dysfunction and progesterone-mediated gynecomastia, though it is less potent and requires daily dosing. Trenbolone's strong progestogenic activity can elevate prolactin substantially. Pramipexole provides a functional alternative for prolactin control during trenbolone cycles, though users with significant prolactin elevation may find cabergoline more reliable. FDA-approved for the treatment of signs and symptoms of idiopathic Parkinson's disease, both as monotherapy and as adjunct to levodopa. Pramipexole is effective at all stages of the disease and is particularly useful for managing motor symptoms in early Parkinson's. FDA-approved for the treatment of moderate-to-severe primary restless legs syndrome. Low doses taken before bedtime significantly reduce RLS symptoms and improve sleep quality.

Join others researching Finasteride — share findings, ask questions, and learn from real experiences Finasteride is an FDA-approved 5-alpha reductase inhibitor that blocks the conversion of testosterone to dihydrotestosterone (DHT), the primary androgen responsible for androgenetic alopecia (male pattern hair loss) and benign prostatic hyperplasia (BPH). At 1mg daily, it reduces scalp DHT levels by approximately 66%, slowing or halting hair loss in roughly 90% of men and producing visible regrowth in about 48% over one to two years. Originally developed for prostate enlargement at 5mg (Proscar), the lower 1mg dose (Propecia) was approved specifically for hair loss in 1997. It remains one of only two FDA-approved oral treatments for androgenetic alopecia and has decades of long-term safety data. Finasteride competitively and selectively inhibits the Type II isoform of the enzyme 5-alpha reductase, which is predominantly found in hair follicles, the prostate, and the liver. This enzyme converts testosterone into dihydrotestosterone (DHT). By blocking this conversion, finasteride reduces serum DHT levels by approximately 70% and scalp DHT by roughly 66% at the 1mg dose. Since DHT is the primary androgen driving miniaturization of hair follicles in genetically susceptible individuals, lowering DHT levels allows affected follicles to recover, extend the anagen (growth) phase, and produce thicker terminal hairs. Notably, finasteride does not block androgen receptors and has minimal effect on testosterone levels, which may increase slightly (by about 10-15%) as a compensatory response to reduced DHT.